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BMI, body mass index 
CM, cardiac metaplasia 
COX-2, cyclooxygenase-2 
D, dysplastic (group) 
ERD, erosive reflux disease 
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GERD, gastroesophageal reflux disease 
GEJ, gastroesophageal junction 
HGD, high-grade dysplasia 
I, intestinal (group) 
IH, immunohistochemistry 
IM, intestinal metaplasia 
LES, lower esophageal sphincter 
LGD, low-grade dysplasia 
lLES, length of lower esophageal sphincter 
LSBE, long-segment Barrett’s esophagus 
NBI, narrow band imaging 
NERD, non-erosive reflux disease 
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pLES, pressure of lower esophageal sphincter 
PPI, proton-pump inhibitor 
PTFE, polytetrafluoroethylene 
PTX, pneumothorax 
rLES, relaxation time of lower esophageal sphincter 
SD, standard deviation 
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1. INTRODUCTION 
 
Gastroesophageal reflux disease (GERD) can be summarized as mucosal irritation, 
inflammation and consequential symptoms caused by the reflux of gastric contents into the 
esophagus due to the impaired function of the gastroesophageal junction (GEJ). It may be 
accompanied by a wide range of symptoms. Most often, the main symptom is heartburn, a 
retrosternal pain which may be caused by the regurgitation of gastric acid into the esophagus. 
In certain cases, it may also be accompanied by dysphagia. Extraesophageal symptoms may 
often be misleading: in case of proximal (high) reflux, airway symptoms may often be 
expected; hoarseness, cough, asthma-like episodes, sinusitis or otitis media may also occur.  
A chest pain of non-cardiac origin or dental caries may also raise the possibility of GERD. 
 
1.1. GASTROESOPHAGEAL REFLUX DISEASE (GERD) 
 
The incidence of GERD shows a significant increase in developed Western countries. 
Approximately 25 to 40 percent of the US population have reflux symptoms once a month.
[1, 2, 
3]
 The incidence of the condition is not lower in Western European countries either; however, 
the incidence decreases towards the East (primarily in Asia).
[4]
 The increase in the incidence 
characteristic to the Western world may be, in part, a relative increase, which can be 
explained by the advance of gastroenterology and the widespread use of 
esophagogastroscopy. However, due to the transition towards a welfare society, an absolute 
increase in the incidence must also be taken into account, which can be explained easily with 
the pathomechanism of the disease: the factors behind the development of GERD include 
changed dietary habits, the appearance of overweight, increased abdominal pressure due to 
the previous factors, the altered diet, and the humoral and reflectory effects of medications 
(that have become part of everyday life) on the reduction of the lower esophageal sphincter 
tone, as well as the anatomical defects (hiatal hernia) developed because of these. These 
increase the reflux that is already physiologically present by overcoming the barrier function 
of the cardiac region. In some cases, depending on the severity of the reflux, the acidic gastric 
contents regurgitating into the esophagus may cause symptoms only, whereas in other cases, 
they may damage the squamous epithelium lining the esophagus, resulting in erosion, 
inflammation and, eventually, ulceration and stricture.
[5]
 The traditional classification of 
7 
 
reflux disease (the Los Angeles Classification)
[6]
 was based on the endoscopic picture, 
differentiating between cases without signs of inflammation (non-erosive reflux disease, 
NERD) and those with erosive esophagitis (ERD) or with complications of severe erosion. 
The Montreal Classification
[7]
, besides the esophageal symptoms, also takes the 
extraesophageal symptoms, i.e., the complaints of the patients, into account. 
In parallel with the severity and duration of GERD, the risk of possible complications also 
increases. Ulcers and/or strictures developed on the basis of inflammation may lead to severe 
dysphagia. The condition of acute abdomen/acute chest due to the perforation of an ulcer or 
stricture may require an urgent (surgical) intervention. Additional possible complications are 
Barrett’s esophagus (BE) and, ultimately, adenocarcinoma developed based on this in the 
lower third of the esophagus. 
 
1.2. BARRETT’S ESOPHAGUS (BE) 
 
The definition of BE can be understood based on its pathogenesis. As “regeneration” of the 
mucosal inflammation and, later, mucosal damage developed due to the persistent acid and/or 
mixed reflux, a columnar epithelium that is more resistant to the acidic environment appears 
next to or replaces the squamous epithelium in the lower third of the esophagus. The 
polymorphism of Barrett’s metaplasia is reflected by the fact that the regeneration starting 
from the esophageal Schaffer glands may have varying histological appearance, possibly with 
multiple histological entities next to each other. Besides intestinal metaplasia (which is 
considered to be the classic form of BE), numerous other forms may appear, including fundic 
or cardiac columnar epithelium, ciliary columnar epithelium, or even pancreatic acinar or 
tubular metaplasia.
[8]
 Although the literature describes the possibility of dysplastic 
transformation in the case of intestinal metaplasia, non-intestinal forms should not be 
disregarded either because of the heterogeneity of the condition (histological forms present 
next to each other or that may transform into each other). 
The endoscopic appearance of the metaplasia can be described most accurately with the 
“Prague C and M” classification[9], which also gives the extension and distance of the lesion 
from the gastroesophageal junction. An extensive BE longer than 3 cm is a so-called long-
segment BE (LSBE), whereas a condition shorter than this is a short-segment BE (SSBE). 
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1.2.1. Epidemiology of Barrett’s esophagus 
 
As to its epidemiology, BE is twice as common in men as in women. A long-term GERD is 
an independent predictive factor of the condition, and its occurrence increases with age: an 
age over 50 years can also be considered an independent predictive factor, as well as the 
Caucasian race.
 [10]
 Although smoking seems to be a risk factor in smaller subpopulations, no 
general conclusion can be drawn from this. According to Swedish studies, both alcohol and 
smoking should be considered independent risk factors.
[11]
 Obesity and a high BMI also 
increase the risk of GERD (rather than that of BE), and thus have only an indirect effect on 
the occurrence of BE.
[12]
 Besides the acidic component in the refluxate, bile acids have a 
significant pathogenic role in the development of BE.
[13,14]
 
The incidence of BE is hard to estimate. With endoscopy becoming a daily routine, it seems 
to be more and more common
[11]
. However, it is important to emphasize that the differences 
in its definition due to the histological polymorphism of the condition also have an effect on 
the numerical epidemiological data.
[11]
 In the West–East comparison, the incidence of BE 
decreases towards the East.
[11]
 The prevalence of BE in the North American and Western 
European population is an estimated 0.9 to 10 percent.
[11,15,16,17,18]
 Based on the data of the 
Surveillance Epidemiology and End Results (SEER) cancer registry, the estimated prevalence 
of BE is 5.6% in the normal population
[19]
. Swedish data calculate with a prevalence of about 
1.6%. In the case of GERD, it may be up to 2.3%. In two-thirds (64%) of the BE cases, SSBE 
is observed. According to a North American study, the prevalence of LSBE among patients 
examined with endoscopy is 0.3 to 2%, and this figure is naturally higher (8 to 20%) if the 
indication for endoscopy was symptomatic GERD. It should be noted that there is 
asymptomatic persistence in the majority of LSBE cases and often, the condition is not even 
recognized. The prevalence of SSBE is higher, between 5 and 30 percent, and there is a 7 to 8 
times higher occurrence of cardiac and specialized intestinal metaplasia than in the case of 
LSBE, although dysplasia is considerably less common in SSBE.
[11]
  
 
Based on cancer registries, esophageal cancer is the eighth most common malignant disease. 
The incidence of esophageal squamous cell cancer in the developed Western world has been 
stagnating or slightly decreasing since the 1970s and 1980s.
[20]
 Contrary to this, the incidence 
of adenocarcinoma is gradually increasing.
[13]
 
Although BE has an important role as the only known and confirmed precancerous condition 
in the development of lower-third esophageal adenocarcinoma, it cannot be considered an 
obligatory condition of it, since, in many cases, BE is not found during the histological 
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examination. Based on large clinical studies, it can be established that the incidence of 
adenocarcinoma in case of BE is 6.1/1000 patient years.
[21]
 The risk in men is twice as high as 
in women.
[13,21]
 As to the process of carcinogenesis, it is supposed that adenocarcinoma is 
developed through the metaplasia–low-grade dysplasia–high-grade dysplasia transition. In 
case of low-grade dysplasia (LGD) developed on the basis of intestinal metaplasia, the risk of 
malignant transformation is increased.
[22]
 According to Stein, the presence of in situ 
carcinoma is almost certain in the case of high-grade dysplasia (HGD).
 [23]
 To summarize, the 
increase in the occurrence of GERD consequentially increases that of BE, which may explain 
the increasing trend in the occurrence of esophageal adenocarcinoma (contrary to what is 
observed in the case of squamous cell cancer) in the developed world.
[20,22]
  
 
1.3. DIAGNOSTICS OF GERD AND BE 
 
Besides the proper evaluation of the patient’s symptoms, many instrumental examination 
methods are available to clarify the diagnosis. Flexible endoscopy, with its advance and 
widespread use, has clearly become the gold standard in the assessment of the esophagus. 
Without a proper endoscopic background, a thorough investigation of neither GERD, nor BE 
can be performed. The new endoscopic examination methods (such as chromoendoscopy, 
NBI, etc.) may help map GERD and BE more precisely. The need for proper professional 
experience and technical equipment warrants the investigations to be performed in centers. 
The objective confirmation and description of reflux and, ultimately, making the indication 
for surgery are also inconceivable without proper functional examinations. The 
gastroenterologist may decide about the correct treatment strategy in the knowledge of the 
presence of acid or bile reflux obtained with pH-metry, impedance monitoring and Bilitec 
monitoring.
[24]
 The information about the function, motility disorders and impairment of the 
esophageal body and sphincters gained during manometry may influence the choice of 
surgical procedure.
 [25]
 A proper biopsy sampling procedure (Seattle protocol)
 [26]
 and a well-
prepared pathological background are also indispensable for detecting the presence of BE. 
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1.4. TREATMENT OF GERD AND BARRETT’S ESOPHAGUS 
 
The conservative (non-surgical) treatment is extremely complex and involves losing weight 
(besides other lifestyle advices), increasing stomach emptying (with prokinetics), protecting 
the esophageal mucosa, and decreasing the acid content of the refluxate. 
Nowadays, the medical treatment is primarily based on effective gastric acid-reducing 
therapies. The symptoms of reflux can be considerably improved with proton-pump inhibitor 
therapy, the use of which may mean an adequate long-term control of reflux. Similarly, they 
can be effective in the treatment of some patients with BE (but there is only indirect evidence 
of their efficacy in the treatment of metaplasia and dysplasia).
[27]
 In case of BE, aspirin in 
increased dose may be added to antacids as chemoprevention, which may reduce the risk of 
transition from metaplasia to dysplasia through the inhibition of COX-2. 
The purpose of the endoscopic treatment of BE is to remove or destroy the affected mucosa 
when dysplasia appears, after which the regeneration restores the squamous epithelium or 
results in a dysplasia-free columnar epithelium if the treatment is combined with successful 
acid inhibitor therapy. Numerous procedures are known from endoscopic mucosal resection to 
submucosal dissection. Ablation may be achieved with radiofrequency therapy but laser 
therapy, argon plasma coagulation, cryotherapy and photodynamic therapy may also be used. 
Out of these methods, however, the depth of the dissection can be reconstructed and an actual 
histological examination can be performed only in the case of endoscopic resections. In the 
rest of the procedures, there is less control of the ablation depth, and the rate of potential 
complications (stricture and, more rarely, perforation) is higher. The indication for endoscopic 
procedures is not clear in case of LGD. A special issue is recurrence in the submucosal 
glandular structures after the endoscopic treatment. In case of LGD, the rate of this may be up 
to 10% in the year following the procedure. However, an advantage of the endoscopic 
procedure is that it can be repeated.
 [28]
 
In case of HGD, the higher relapse rate after endoscopic procedures or the appearance of 
carcinoma may require surgical intervention. The presence of in situ carcinoma is almost 
certain in the case of HGD; however, neither this, nor an early carcinoma means a 
contraindication to endoscopic procedures.
 [28]
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1.4.1 Surgical Treatment 
 
The various antireflux procedures have long been accepted in the surgical treatment of GERD 
and BE. Nowadays, with the spread of minimally invasive surgical methods, laparoscopic 
antireflux procedures that have low mortality rates have become equivalent alternatives to 
conservative treatment. In case of proper indication, the correctly performed procedure 
successfully decreases the acid and bile reflux, and also restores the function of the lower 
esophageal sphincter. In case of BE, with the reflux gone, we may suppose that the 
progression of metaplastic and dysplastic processes is stopped and that regression is achieved. 
The long-term success of antireflux procedures, similarly to that of medical treatment, is 
contradictory, as well as their role in the prevention of adenocarcinoma. In cases of BE with 
LGD, better results may be expected from the combination of mucosal ablation and medical 
or surgical treatment. In cases of HGD, in situ carcinoma and early cancer, distal esophageal 
and cardiac resection may be considered an oncologically adequate treatment from a surgical 
point of view. In case of invasive adenocarcinoma, esophageal resection may be performed. 
 
2. PROBLEMS AND OBJECTIVES 
 
The increase in the incidence of esophageal adenocarcinoma calls the importance of this 
condition to our attention. The key for the successful treatment of esophageal adenocarcinoma 
is the prevention of its development or its early recognition. The only precancerous condition 
of esophageal adenocarcinoma confirmed to date is BE. In our clinical study, we intended to 
establish the clinical risk factors of the development of BE, the prevention of its development, 
and the possible strategy for its surgical treatment. 
 
1. An objective of our work was to understand the potential clinical risk factors and 
relationships playing a role in the development of BE and the process of the Barrett’s 
metaplasia—dysplasia—carcinoma transformation through the study of patients with GERD 
and BE (Study 1). 
 
2. A further objective was to study the efficacy of surgical treatment (laparoscopic antireflux 
procedure) among patients subjected to surgery because of either GERD or BE (Study 2). 
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3. During our short-term and long-term follow-up, the effect of laparoscopic antireflux 
procedure on the histological changes of Barrett’s esophagus, as well as its possible 
preventive effect in the process of carcinogenesis were studied (Study 3). 
 
4. The early and late complications of the antireflux procedure were studied (Study 4). 
 
5. The successful endoscopic treatment of spontaneous esophageal perforation, a rare 
complication of BE, is presented through one of our cases (Study 5). 
 
3. PATIENTS AND METHODS 
3.1. COMPARISON OF PATIENTS SUBJECTED TO SURGERY BECAUSE OF 
GERD OR BE (STUDY 1) 
Our retrospective clinical study was based on patients subjected to surgery because of GERD 
or reflux disease accompanied by Barrett’s esophagus at the Department of Surgery of the 
Faculty of Medicine of the University of Szeged between January 1, 2001 and December 31, 
2008. Nissen’s laparoscopic antireflux procedure was performed in 176 cases because of 
GERD (Group 1) and in 78 cases because of BE (Group 2). 
In Study 1, the results of the preoperative assessment were compared between the above two 
patient groups. 
 
3.2. CLINICAL RISK FACTORS OF THE DEVELOPMENT OF BE 
As a continuation of Study 1, patients in the BE group (78 patients) were divided into three 
further groups on the basis of the histological results of their preoperative endoscopic 
biopsies: a non-intestinal group (NI, 53 patients) with fundic (FM) and cardiac metaplasia 
(CM), an intestinal group (I, 18 patients) with intestinal metaplasia (IM), and a dysplastic 
group (D, 7 patients) with LGD. BE involved a short segment (< 3 cm, SSBE) in 67 cases 
(85.9%) and a long segment (> 3 cm, LSBE) in 11 patients (14.1%). We compared the results 
of the preoperative assessment between these three groups.  
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3.3. COMPONENTS OF THE PREOPERATIVE ASSESSMENT 
3.3.1. Endoscopy 
 
The esophagogastroscopy performed as part of the preoperative gastroenterological 
assessment to confirm the reflux disease was the first step of the standard examination, during 
which the gastroesophageal junction was examined. Hiatal hernia is diagnosed if the 
impression of the diaphragmatic crura is widened by more than 2 cm. Its size is given in 
centimeters. The reflux disease was described based on the Los Angeles Classification.
 [6]
 
Biopsy was performed (in all four quadrants, with 2-cm intervals) to confirm or rule out 
Barrett’s metaplasia (Seattle protocol). [26] Barrett’s esophagus was characterized based on the 
Prague C & M Criteria.
 [9]
 
3.3.2. Histological Examination 
 
The formalin-fixed, paraffin-embedded histological samples were assessed for Barrett’s 
metaplasia or dysplasia after hematoxylin-eosin and immunohistochemistry staining 
(Figure 1). In our study, samples with either fundic or cardiac or intestinal metaplasia were 
included. In case of BE with LGD described during the histological examination, two 
experienced pathologists also examined the slides. 
 
 
FM,    CM,    IM  
 
      LGD,         HGD,   COX-2 activity 
Figure 1. Histological examination of BE. 
Hematoxylin-eosin staining and immunohistochemistry. 
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3.3.3. Functional Examinations 
 
Esophageal pH-metry 
Of the functional examinations, 24-hour pH-metry was performed in each case. The acid 
reflux was measured with a pH electrode inserted nasally and secured 5 cm above the upper 
margin of the lower esophageal sphincter (LES). The probe recorded the acid reflux episodes 
for 24 hours—esophageal pH decrease below 4, number of reflux episodes longer than 
5 minutes, duration of the longest reflux episode, percentage of time of exposure to pH below 
4, and the DeMeester composite score, out of which the DeMeester score and the percentage 
of time of exposure to pH below 4 have the highest sensitivity (96%) and specificity (100%). 
Their normal value, based on studies conducted with health volunteers, is 14.7 and 4.2%, 
respectively.
[29,30,31,32,33]
 
Esophageal manometry 
During the manometry, the motor function of the esophagus was examined with a catheter 
inserted nasally into the esophagus, using the standard distilled water perfusion method, and 
mapping the function of the entire esophageal body, the pharyngoesophageal junction and the 
LES: the length of the sphincter (lLES), its mean pressure (pLES), its relaxation (rLES), the 
amplitude and duration of the contractions of the esophageal body, and (optionally) 
pharyngeal motility. The generally accepted values for the UES are a length of 2 to 5 cm and 
a mean pressure of 40 to 100 mmHg; and for the LES, a length of 2 to 4 cm and a mean 
pressure of 10 to 40 mmHg. The pressure in the lower third of the esophagus during 
swallowing is 20 to 170 mmHg.
[29,34,35,36]
 
Bilitec 
In both groups, Bilitec monitoring was performed only in cases where bile regurgitation was 
suspected during endoscopy. The nasally inserted catheter was positioned 5 cm above the 
LES, and the photoabsorption (at 450 nm) of bile acids reaching the esophagus was detected 
with a fiber optic spectrophotometer.
[29, 30,31,32]  
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3.4. SURGICAL TREATMENT, SURGICAL TECHNIQUE 
After the gastroenterological assessment, patients with GERD and BE underwent elective 
surgery. Laparoscopic antireflux procedure with Nissen’s 360-degree fundoplication was 
performed on the patients of both groups. During the standardized steps of the procedure, the 
flaccid part of the lesser omentum was opened while retracting the left lobe of the liver, and 
then the diaphragmatic crura were prepared (first the right, and then the left one), going 
around the entire circumference of the esophagus, mobilizing this way its abdominal segment. 
The fundus was mobilized by transecting the gastrosplenic ligament and the short arteries and 
veins running within it. The posterior reconstruction of the diaphragmatic crura was 
performed with interrupted stitches (using non-absorbable suture). After this, 360-degree 
(Nissen’s) fundoplication was performed in each case. Partial (Toupet) and anterior (Dor) 
fundoplications were excluded from the study. 
During the surgeries, a mesh was placed because of the large hiatal hernia in 14 cases. The 
indication for this was the unsuccessful tension-free closure of the diaphragmatic crura. A 
PTFE mesh was used for the reconstruction, which was secured with a spiral clamp. 
Gastropexy was performed in 6 cases in the GERD group, and a mesh was also placed in each 
of these cases because of a large hiatal hernia. In 26 cases, cholecystectomy was also 
performed in the same session because of the accompanying cholelithiasis.  
 
3.5. POSTOPERATIVE FOLLOW-UP (STUDY 2) 
During Study 2, the efficacy of procedures performed because of GERD or BE were 
compared based on subjective measures (Visick score) and the results of early functional 
examinations. 
 
Assessment of symptoms and objective measures of outcome 
Visick grading was used to assess the effect of surgery on the symptoms: complete resolution 
(Grade I); an improvement (Grade II); no effect of surgery (Grade III); or deterioration 
relative to the preoperative state (Grade IV). This scoring system was devised to give an 
overall impression of the benefits of antireflux surgery because it exhibits good correlation 
with heartburn, the most prominent symptom of GERD.
[37]
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In the postoperative period, patients were subjected to follow-up surgical and medical 
examinations. Postoperative functional examinations, such as esophageal manometry, 24-hour 
pH-metry and, in reasonable cases, bile exposure (Bilitec) monitoring and endoscopy were 
performed in the early postoperative period with an average follow-up period of 13.8 ± 
19.31 months in the GERD group and 16.7 + 17.00 months (range: 3–23) in the BE group.  
 
3.6. ENDOSCOPIC AND HISTOLOGICAL FOLLOW-UP OF PATIENTS 
SUBJECTED TO LAPAROSCOPIC ANTIREFLUX PROCEDURE BECAUSE OF BE 
(STUDY 3) 
During the study, in the later postoperative period, an additional upper endoscopy with biopsy 
was carried out in the BE subgroups to assess the changes in BE. The overall average follow-
up time was 42 + 16.19 months (range: 3–61).  
 
3.7. STUDY OF THE COMPLICATIONS OF THE ANTIREFLUX PROCEDURE 
(STUDY 4) 
 
The early complications of laparoscopic antireflux procedure are well known. Bleeding may 
start from the vessels that supply the stomach (left gastric artery and vein and short gastric 
arteries and veins). Spleen injury during the mobilization of the fundus may be a severe 
condition that often requires conversion. Injury to the hepatic capsule and bleeding of the liver 
are rarely severe complications. Rarely, the iatrogenic or ischemic perforation of a hollow 
organ (esophagus, stomach) may require an intraoperative solution or early reoperation. 
Subcutaneous emphysema due to the insufflation, which involves less risk, rarely requires 
surgical intervention. Pneumothorax accompanying pleural injuries in the posterior 
mediastinum, however, may require pleural drainage in certain cases. Impaired gastric 
emptying as a consequence of injury to the vagus nerve fibers may cause complaints in the 
long term. 
 
Among the late complications of the surgical treatment, persistent cases of dysphagia must be 
mentioned first, the treatment of which, similarly to making the indication for surgery, 
requires a close cooperation between the gastroenterologist and the surgeon. In case of an 
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unsuccessful dilation with bougies, balloon dilation may be required. In case of large hiatal 
hernias, the placement of a mesh exposes the patient to special hazards. Erosion of the 
esophageal wall may be a severe or even life-threatening condition, and it is to be treated 
surgically with relative urgency: often, cardiac resection and jejunal interposition 
(Merendino’s procedure) are required. 
 
3.8. COMPLICATIONS OF BE (STUDY 5) 
Stricture, bleeding, perforation and, ultimately, malignant transformation on the basis of 
Barrett’s ulcer are well-known complications. Perforation as a consequence of Barrett’s ulcer 
or a stricture is most often iatrogenic. Spontaneous perforation is an extremely rare, life-
threatening condition. The successful endoscopic treatment of this rare complication will be 
presented through a case report. 
 
3.9. STATISTICAL ANALYSIS 
The values measured and summarized during the clinical study of the GERD and BE groups 
were evaluated using SigmaStat
®
 3.1, comparing the groups with a two-sample t test and the 
Mann–Whitney Rank Sum test. Further statistical calculations were performed with SPSS 
17.0 for Windows, whereas the special Poisson-distributed ANOVA method was performed 
with SAS for Windows 9.1.
[38]
 Preoperative univariate analyses were performed to identify 
factors associated with the occurrence of histopathological progression: a non-parametric 
method (Kruskal–Wallis test) was used for the analysis of variables. Non-parametric 
univariate analyses (Mann–Whitney test) were performed to estimate the efficacy of 
laparoscopic antireflux surgery, comparing the variables before and after surgery. To compare 
changes in the patients’ parameters before and after the operation in the three BE groups, a 
generalized mixed model repeated measurements ANOVA method was applied (multivariate 
analysis), using the GLIMMIX procedure of SAS 9.1. One repeated measurement factor 
(antireflux surgery), one independent factor (groups) and their interaction were examined. The 
distribution of the variables and the differences of variations in the three BE groups were also 
taken into account. P values < 0.05 were considered statistically significant. 
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4. RESULTS 
4.1 COMPARISON OF PATIENTS SUBJECTED TO SURGERY BECAUSE OF 
GERD OR BE (STUDY 1) 
According to the results of Study 1, the gender distribution in the two patient groups showed a 
predominance of women (112 women, 64 men), with a more balanced ratio in cases 
complicated with Barrett’s esophagus (40 women, 38 men) but, contrary to literature data, 
there was no male predominance in this group either (Table 1). There was no difference 
between the two groups in mean patient age (Group 1: 53.87 ± 12.04 years vs. Group 2: 53 ± 
12.7 years, p=0.495) or mean BMI (Group 1: 26.91 ± 4.54 vs. Group2: 28.31 ± 5.46, 
p=0.451). It must be noted, however, that the majority of patients in both groups were 
overweight, which is a known potential risk factor of reflux disease (Table 1). 
 
 
GERD 
mean and SD 
BE 
mean and SD 
MEAN AGE (years) 53.87±12.04 53.03±12.70 
GENDER DISTRIBUTION 
(MEN/WOMEN) 64/112 38/40 
BMI 26.91±4.54 28.31±5.46 
HISTORY (MONTHS) 68.86±32.63 68.98±60.89 
DURATION OF MEDICAL THERAPY 
(MONTHS) 19.87±25.17 19.20±27.31 
RATE OF HIATAL HERNIA (%) 75.56 64.10 
SIZE OF HIATAL HERNIA (CM) 3.50±1.59 3.73±1.71 
 
Table 1. Demographics and historical data of patients with GERD and BE 
There was no statistical difference in the demographics between GERD and BE patients. 
 
As to the results of the preoperative assessment, contrary to our hypothesis, there was no 
difference between the two groups in the mean time from the onset of symptoms to the 
surgery (p=0.653). A relatively long history was observed in both patient groups (68.86 ± 
32.63 months in Group 1 and 68.98 ± 60.89 months in Group 2) (Table 1). In both groups, the 
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complaints of the patients mostly included heartburn, epigastric or chest pain, acid or bile 
belching, dysphagia, loss of appetite, nausea, and vomiting.  
In all of the cases, surgery was performed after an unsuccessful acid-reducing medical therapy 
(mean duration of treatment: 19.87 ± 25.17 months in Group 1 and 19.20 ± 27.31 months in 
Group 2). As expected, hiatal hernia was common among the patients (in 75.42% in Group 1 
[133 cases] and in 64.10% in Group 2 [50 cases]). Its mean size, however, was almost the 
same in the two groups (3.48 ± 1.59 vs. 3.73 ± 1.71 cm [p=0.296]) (Table 1). A mesh was 
placed because of a large hiatal hernia in 10 cases (5.7%) in Group 1 and in 4 cases (5.1%) in 
Group 2. 
The theory according to which bacterial colonization, and metabolites produced during 
bacterial metabolism, are potentially carcinogenic, was not supported in the case of BE by the 
Helicobacter pylori infection observed in the stomach (confirmed in 27% in Group 1 and in 
only 22% in Group 2). Besides the reflux, the accompanying gastritis was also often observed 
during the endoscopic examination. 
4.1.1. Preoperative Functional Results 
Manometry 
Although it can be established that the LES function measured with manometry was impaired 
in both groups, thus allowing abnormal acid and/or bile reflux, there was no difference 
between the two groups in the mean values of LES pressure (12.10 ± 7.93 mmHg vs. 12.57 ± 
9.03 mmHg [p=0.892]), relaxation time (10.39 ± 2.99 sec vs. 10.36 ± 2.81 sec [p=0.773]) and 
length (3.30 ± 1.84 cm vs. 3.17 ± 1.45 cm [p=0.377]) (Table 2). 
pH-metry 
Based on the results of pH-metry—in accordance with the pathomechanism of the disease—
the acid reflux was more severe in patients subjected to surgery because of Barrett’s 
esophagus than in those with reflux disease alone. During the pH-metry performed 5 cm 
above the cardia, the total number of reflux episodes (measured over 24 hours), the number of 
upright episodes, the number of supine episodes, the number of postprandial episodes, the 
number of episodes longer than 5 minutes, and the value of the longest episode were all 
significantly higher in Group 2 (p<0.001). The DeMeester score was also higher in Group 2 
(18.9 vs. 41.9, p<0.001) (Table 2). 
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PREOPERATIVE FUNCTIONAL RESULTS GERD BE p value 
LES mean±SD mean±SD  
PRESSURE (mmHg) 12.10±7.93 12.58±9.03 NS 
RELAXATION TIME (sec) 10.39±2.99 10.37±2.81 NS 
LENGTH (cm) 3.02±1.84 3.17±1.45 NS 
    
pH-METRY    
Total time of acid exposure <pH 4 65.62±69.39 123.11±134.71 <0.001 
Upright acid exposure <pH 4 55.37±58.21 97.84±112.53 <0.001 
Supine acid exposure <pH 4 11.00±23.21 25.49±36.68 <0.001 
Postprandial acid exposure <pH 4 31.34±34.42 55.55±57.77 <0.001 
>5 min acid exposure <pH 4 2.20±3.64 4.55±6.72 <0.001 
Longest acid exposure <pH 4 12.04±17.50 25.96±49.80 <0.001 
DeMeester score 18.85±21.39 41.93±51.15 <0.001 
    
Bilitec    
Total time of bile exposure 10.50±17.72 26.97±28.79 <0.001 
Upright bile exposure 10.33±17.79 17.41±19.70 NS 
Supine bile exposure 0.17±0.39 9.80±15.17 NS 
Postprandial bile exposure 5.58±10.01 8.30±9.84 NS 
>5 min bile exposure 2.00±4.24 6.69±9.53 <0.001 
Longest bile exposure 16.17±20.44 82.96±105.14 <0.001 
 
Table 2. Results of preoperative functional examinations in patients with GERD and BE 
Based on the preoperative functional examinations, the impairment of the function (pressure) 
of the LES was the same in both patient groups. Patients with BE were characterized by more 
severe and more frequent acid reflux episodes. 
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Bilitec 
Bilitec monitoring was performed only in a limited number of GERD cases, primarily if bile 
reflux was suspected during endoscopy. Because of the selected cases, a statistical conclusion 
cannot be drawn; however, in view of the Bilitec results, it can be established that the values 
of the total time of bile reflux and the number of bile reflux episodes longer than 5 minutes 
were higher, and the longest bile reflux episode was longer in the case of patients subjected to 
surgery because of Barrett’s esophagus (Table 2). 
4.1.2. Comparison of the functional examinations of patients subjected to surgery 
because of BE based on the histological severity of BE  
 
Preoperative characteristics of the BE patient population (NI, I and D groups) 
Contrary to our expectations, IM and LGD did not show a longer history of reflux disease 
when compared with the NI group, and history was longer in the NI group than in the I group 
(p=0.057) (Table 1). The duration of medical treatment showed no difference either. Although 
patients were overweight in all 3 groups, there was no difference in mean BMI. Hiatal hernia 
was present with the same incidence in cases of more severe BM and LGD, but it was not 
significantly higher than in the NI group. No statistical difference was detected between the 
3 groups in the LES function (pressure, length and relaxation time). In accordance with 
literature data, our research results revealed more severe acid reflux in patients with BE than 
in patients with mild GERD alone. With respect to acid reflux, however, BE did not exhibit 
any difference. The parameters used to calculate the DeMeester score did not differ 
significantly between the 3 groups. In comparison with the NI group, a higher DeMeester 
score was observed only in the D group, but this difference was not significant. The majority 
of the values measured during the Bilitec monitoring indicated more severe bile reflux in the 
D group than in the other 2 groups (Table 3). In contrast with the results of the univariate 
analyses, the multivariate analysis did not demonstrate significant differences between the 
three preoperative groups. 
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    Group Mean SD p value 
P
a
ti
en
ts
’ 
ch
a
ra
ct
er
is
ti
cs
         NI 27.70 5.58   
BMI I 29.93 5.67 p=0.354 
 D 28.30 4.09   
       NI 3.07 1.95   
Hiatal hernia (cm) I 3.08 2.4 p=0.395 
 D 4.20 1.17   
      
Mean time (years) from appearance of first symptoms to surgery 
NI 5.80 4.53   
I 3.94 5.25 p=0.057 
D 4.29 5.15   
       NI 1.47 2.56   
PPI treatment (y) I 1.00 0.97 p=0.537 
 D 4.14 5.27     
                  
M
a
n
o
m
et
ry
 pLES (mmHg) 
NI 11.27 8.19   
I 13.31 8.84 p=0.382 
D 8.40 8.85   
      
rLES (s) 
NI 10.51 3.32   
I 10.09 1.97 p=0.937 
D 10.00 0.82   
      
lLES (cm) 
NI 2.98 1.37   
I 3.54 1.90 p=0.757 
D 3.00 0.82     
                  
p
H
-m
et
ry
 
Total time of acid exposure <pH 4 
NI 100.64 78.11   
I 111.12 104.80 p=0.835 
D 274.20 359.82   
      
Upright acid exposure <pH 4 
NI 80.10 70.91   
I 93.18 92.16 p=0.832 
D 229.00 302.06   
      
Supine acid exposure <pH 4 
NI 20.67 25.10   
I 18.35 29.21 p=0.374 
D 45.60 60.65   
      
Postprandial acid exposure <pH 4 
NI 47.28 38.05   
I 50.88 55.35 p=0.748 
D 113.20 136.51   
      
>5 min acid exposure <pH 4 
NI 3.90 4.76   
I 5.06 10.05 p=0.299 
D 8.00 8.80   
      
Longest acid exposure <pH 4 
NI 25.10 60.13   
I 15.24 20.97 p=0.469 
D 43.20 48.98   
      
DeMeester score 
NI 34.95 43.84   
I 39.12 61.01 p=0.145 
D 88.92 67.58     
                  
B
il
it
ec
 
Total time of bile exposure 
NI 22.38 22.90   
I 23.33 30.53 p=0.025 
D* 70.75 32.52   
      
Upright bile exposure 
NI 13.88 17.64   
I 16.60 15.77 p=0.027 
D* 48.75 28.36   
      
Supine bile exposure 
NI 8.66 12.16   
I 6.80 19.04 p=0.017 
D* 23.00 14.90   
      
Postprandial bile exposure 
NI 6.78 9.30   
I 8.00 7.85 p=0.087 
D 20.50 16.84   
      
>5 min bile exposure 
NI 6.97 10.27   
I 3.00 2.90 p=0.021 
D* 17.50 14.39   
      
Longest bile exposure 
NI 87.16 107.20   
I 38.60 63.72 p=0.195 
D 111.25 37.95   
        
Table 3. Characteristics of the three preoperative groups (NI, I and D) (78 patients) 
*Comparison of the preoperative BE groups revealed significantly more severe bile reflux in 
the D group than in the other two groups. (Non-parametric method—the Kruskal–Wallis test 
was applied) 
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4.2. POSTOPERATIVE RESULTS (STUDY 2) 
In part 2 of the study, the efficacy of the antireflux surgery was assessed in view of the 
postoperative results. 
 
4.2.1. Symptomatic Outcome 
Based on the Visick score
[17]
 determined in Group 1 after the surgery, at the early surgical 
follow-up visit (at 3 months), complaints were gone or improved in 73% of the patients, they 
were unchanged in 15%, and 12% of the patients reported worsening, primarily with a leading 
symptom of dysphagia. In Group 2, 81% of the patients were complaint-free or reported 
improved symptoms, 15% had unchanged complaints, and worsening was observed in 4%. 
Dysphagia was the predominant symptom also in this group. 
 
4.2.2. Postoperative Functional Results 
After the surgery, patients were subjected to follow-up functional examinations and 
endoscopy; the mean follow-up time was 13.8 ± 19.31 months in Group 1 and 16.7 ± 
17.00 months in Group 2. The mean LES pressure was significantly increased compared with 
the preoperative value in both groups (17.58 ± 7.60 mmHg in Group 1 and 18.70 ± 
6.74 mmHg in Group 2). After the surgery, the LES length and relaxation time did not show a 
statistically significant difference compared with the preoperative values (Table 4). 
Based on the follow-up pH-metry, the number and duration of acid reflux episodes 
significantly decreased in both groups. The postoperative DeMeester scores returned to the 
normal range: they decreased to a mean score of 7.7 ± 17.41 in Group 1 and 12.7 ± 30.74 in 
Group 2. When following the patients subjected to Bilitec monitoring before the surgery, a 
decrease in the occurrence of bile reflux was also observed (Table 4). 
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FUNCTIONAL RESULTS GERD BE 
 Preop Postop p value Preop Postop p value 
LES mean ± SD mean ± SD  mean ± SD mean ± SD  
PRESSURE (mmHg) 12.10±7.93 17.58±7.60 <0.001 12.58±9.03 18.70±6.74 <0.001 
RELAXATION TIME (s) 10.39±2.99 9.31±2.60 NS 10.37±2.81 10.25±2.22 NS 
LENGTH (cm) 3.02±1.84 3.39±1.34 NS 3.17±1.45 3.48±1.85 NS 
       
pH-METRY       
Total time of acid exposure <pH 
4 
65.62±69.39 18.04±37.96 <0.001 123.11±134.71 47.08±89.16 <0.001 
Upright acid exposure <pH 4 55.37±58.21 14.33±33.43 <0.001 97.84±112.53 37.18±71.51 <0.001 
Supine acid exposure <pH 4 11.00±23.21 3.53±8.77 <0.001 25.49±36.68 9.96±22.63 <0.001 
Postprandial acid exposure <pH 4 31.34±34.42 8.38±21.15 <0.001 55.55±57.77 22.02±43.14 <0.001 
>5 min acid exposure <pH 4 2.20±3.64 0.56±2.14 <0.001 4.55±6.72 0.80±2.20 <0.001 
Longest acid exposure <pH 4 12.04±17.50 6.24±20.75 <0.001 25.96±49.80 3.58±5.82 <0.001 
DeMeester score 18.85±21.39 7.73±17.41 <0.001 41.93±51.15 12.72±30.74 <0.001 
       
Bilitec       
Total time of bile exposure 10.50±17.72 17.00±22.24 NS 26.97±28.79 22.08±30.57 <0.001 
Upright bile exposure 10.33±17.79 15.25±19.38 NS 17.41±19.70 18.24±26.14 NS 
Supine bile exposure 0.17±0.39 2.00±3.37 NS 9.80±15.17 3.92±7.78 NS 
Postprandial bile exposure 5.58±10.01 9.00±13.47 NS 8.30±9.84 7.52±11.16 NS 
>5 min bile exposure 2.00±4.24 2.50±3.00 NS 6.69±9.53 3.00±4.61 <0.001 
Longest bile exposure 16.17±20.44 53.50±46.94 NS 82.96±105.14 58.88±131.77 <0.001 
 
Table 4. Results of postoperative functional examinations in patients with GERD and BE 
The postoperative functional examinations confirmed an increase in LES pressure and a 
decrease in bile reflux in both groups. 
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4.2.3. Postoperative Results by BE Subgroup (Study 3) 
 
In part 3 of the study, the rate of BE regression was studied in function of the laparoscopic 
antireflux surgery. The early quality of life measures, the results of the early postoperative 
functional examinations and the long-term endoscopic follow-up results were summarized for 
the three BE subgroups.  
4.2.3.1. Early postoperative results 
4.2.3.1.1. Symptomatic outcome 
The Visick score varied somewhat within the groups—in patients with intestinal BE and also 
in those with LGD, complaints were alleviated relative to those with NI metaplasia. The 
assessment of the changes in both the subjective and objective complaints demonstrated that 
the symptoms recorded during the preoperative period tended to be relieved after laparoscopic 
Nissen fundoplication. In accordance with our expectations, dysphagia increased. 
 
4.2.3.1.2. Postoperative functional examinations (manomentry, 24-hour pH studies and Bilitec) 
Postoperative manometry, pH-metry and Bilitec monitoring did not reveal statistically 
significant differences between the three groups. Changes in the LES function, which also 
indicate the efficacy of the surgery, demonstrated that the postoperative pressure in the lower 
esophagus was significantly increased relative to that measured preoperatively, whereas the 
relaxation time remained unchanged. As a consequence of the surgical technique (a loose and 
narrow Nissen floppy), the length of the LES was unchanged after fundoplication, but its 
function (pressure) was restored, thus preventing acid and bile reflux. Comparison of the 
results of pH-metry before and after the procedure between the three groups confirmed the 
above findings, as mean DeMeester scores were clearly decreased after the surgery. 
Accordingly, the incidence and severity of bile reflux were reduced, or this symptom was 
eliminated. The multivariate analysis confirmed significant changes only in LES pressure and 
the results of pH-metry between the preoperative and postoperative groups. 
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4.3 RESULTS OF THE ENDOSCOPIC FOLLOW-UP OF THE BE SUBGROUPS 
(ENDOSCOPIC SURVEILLANCE) - Long-term endoscopic surveillance  
The mean duration of endoscopic follow-up was 42 + 16.19 months. Postoperative endoscopy 
was performed only in 64 patients (82%, 64/78). 14 patients, who were not subjected to upper 
gastrointestinal endoscopy, were excluded from the long-term analysis. 
Before the antireflux surgery, SSBE was present in 56 patients and LSBE in 8 patients. 
Preoperative histological examinations indicated FM in 11, CM in 33, IM in 15 and LGD in 
5 patients. The postoperative check-up demonstrated a total regression of BE in 10 patients 
(15.6%). Partial regression was seen in 9 cases (14.1%), no further progression in 34 patients 
(53.1%), and progression from FM to CM in 4 patients (6.2%) or from CM to IM in 
7 patients (11%), but no cases of dysplastic or malignant transformation were recorded. 
There was no further progression in the patients with LGD, and in 3 of these 5 patients, LGD 
disappeared, leaving only residual IM (Table 5).  
 
 Complete regression Partial regression No change Progression 
Overall group     
SSBE (n=56) 10 (17.9%) 5 (8.9%) 30 (53.6%) 11 (19.6%)** 
LSBE (n=8) 0 4 (50%) 4 (50%) 0 
 
NI* (n=44) 6 (13.6%) 4 (9.1%) 23 (52.3%) 11 (25%)** 
IM (n=15) 3 (20%) 3 (20%) 9 (60%) 0 
LGD (n=5) 1 (20%) 2 (40%) 2 (40%) 0 
Total (n=64) 10 (15.6%) 9 (14.1%) 34 (53.1%) 11 (17.2%)** 
 
Table 5. Endoscopic and histopathological changes of BE after laparoscopic fundoplication 
(64 patients) 
Complete regression of BE was defined as the absence of any visible metaplasia on 
endoscopy and the absence of columnar metaplasia on histopathological examination. Partial 
regression was defined as a regression from LSBE to SSBE, or a regression from dysplasia to 
metaplasia, or changes within the metaplastic group (IM>CM>FM). Aggravation of the 
disease was defined as changes within the metaplastic group (FM<CM<IM), or progression 
from metaplasia to dysplasia or from SSBE to LSBE. Results are expressed as numbers of 
patients with percentages in parentheses. 
* NI, including fundic and cardiac metaplasias 
** progression from FM to CM in 4 patients and from CM to IM in 7 patients; no further 
progression in patients with IM or LGD 
27 
 
 
There was no difference in the length of the follow-up period between the total regression 
group and the other groups (partial, no change and progression). Where the regression of BE 
was observed, the postoperative functional examination results of manometry (pLES) and pH-
metry were significantly better compared with those measured in the groups where no 
changes in BE occurred, or progression of BE was found. We did not find differences 
between the groups in the results of postoperative Bilitec monitoring, except for the longest 
exposure values (Table 6). 
 
 
  Groups  
  Regression (SD) No change (SD) Progression (SD) p value 
M
a
n
o
m
et
ry
 
pLES (mmHg) 18.04 (±6.405) 9 (±7.735) 11.02 (±7.815) 0.003 
rLES (s) 10.04 (±1.613) 10.03 (±2.831) 9.89 (±4.285) 0.988 
lLES (cm) 3.21 (±0.699 3.14 (±1.424) 2.89 (±1.269) 0.571 
 
    
p
H
-m
et
ry
 
Total time of acid 
exposure <pH 4 23.77 (±25.21) 105.29 (±89.191) 112.2 (±82.974) <0.001 
Upright acid 
exposure <pH 4 21.23 (±24.1229 79.79 (±67.776 87.9 (±74.929) 0.002 
Supine acid 
exposure <pH 4 2.62 (±3.595 25.75 (±33.216) 24.6 (±21.798) 0.002 
Postprandial acid 
exposure <pH 4 12.42 (±16.649) 48.63 (±46.04) 61.3 (±53.506) 0.009 
>5 min acid 
exposure <pH 4 0 (±0) 5.46 (±8.495) 5.1 (±5.607) <0.001 
Longest acid 
exposure <pH 4 1.38 (±1.557) 19.33 (±27.223) 19.6 (±15.82) <0.001 
DeMeester score 3.52 (±3.617) 40.88 (±51.37) 43.089 (±6.094) <0.001 
 
 
    
B
il
it
ec
 
Total time of bile 
exposure 4.75 (±6.292) 32.05 (±34.861) 23 (±28.605) 0.097 
Upright bile 
exposure 4 (±4.83) 19.21 (±22.062) 15.89 (±18.395) 0.143 
Supine bile 
exposure 0.75 (±1.5) 13.05 (±19.478) 7.44 (±12.69) 0.295 
Postprandial bile 
exposure 1 (±1.414) 8.11 (±10.954) 7.89 (±10.55) 0.117 
>5 min bile 
exposure 0.75 (±1.5) 9.05 (±13.206) 6.33 (±9.206) 0.138 
Longest bile 
exposure 3.25 (±5.188) 81.72 (±99.8) 72.78 (±93.641) 0.050 
      
 
Table 6. Comparison of the postoperative functional examinations and the changes in BE 
(between the three groups: regression, no change, progression (64 patients). 
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4.4. COMPLICATIONS OF MINIMALLY INVASIVE ANTIREFLUX PROCEDURES 
AND THEIR TREATMENT (STUDY 4) 
 
4.4.1. Surgical complications 
In part 4 of our study, the risk of the surgical treatment was evaluated. We processed the data 
on surgical complications of patients subjected to surgery because of GERD or BE between 
2001 and 2008. Intraoperative complications, as well as early (within 30 days) and late 
complications were analyzed in detail. 
 
4.4.2. Intraoperative and early surgical complications 
Conversion was required in 1 case in the GERD group because of adhesions. Open 
splenectomy (requiring postoperative transfusion) was performed in 1 case in the BE group 
because of spleen bleeding. Intraoperative chest tube insertion was required in 1 case in the 
GERD group because of left-sided pneumothorax. Reoperation was not performed in either 
group in the early postoperative period. In the GERD group, 2 patients were given a total of 
6 units of pRBC because of bleeding, and subcutaneous emphysema was detected in 1 case, 
which did not require further treatment. 
 
4.4.3. Late surgical complications between 2001 and 2008 
During the early and late follow-up in the GERD group, observation at the institution was 
required in 3 cases because of dysphagia and stenosis: in 1 case, the complaints of the patient 
resolved spontaneously, in 1 case, endoscopic foreign body retrieval was performed because 
of food bolus obstruction (in the early period), and in 1 case, endoscopic balloon dilation was 
performed (in the late period). Usually, a satisfactory result was achieved with dilation, and 
reoperation has not been required in our practice to date. Endoscopic follow-up described the 
appearance of ulcer in 2 cases in the GERD group, and in 2 cases, BE was developed. In 
1 case, cardiac resection was needed because of erosion due to the implanted mesh 7 months 
after the surgery. In the BE group, esophageal dilation was performed because of dysphagia in 
2 cases. There were no mortalities in either group. 
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GERD 
176 PATIENTS NOTE 
BE 
78 PATIENTS NOTE 
INTRAOPERATIVE COMPLICATIONS     
CONVERSION 1 (0.57%) ADHESION 1 (1.28%) 
SPLEEN 
INJURY 
PNEUMOTHORAX 1 (0.57%)  0  
EARLY POSTOPERATIVE 
COMPLICATIONS     
TRANSFUSION 2 (1.14%)  1 (1.28%)  
SUBCUTANEOUS EMPHYSEMA (MAJOR) 1 (0.57%)  0  
LATE POSTOPERATIVE 
COMPLICATIONS     
SEVERE DYSPHAGIA 3 (1.71%)  2 (2.56%)  
APPEARANCE OF ULCER 2 (1.14%)  0  
DEVELOPMENT OF BE 2 (1.14%)  –  
MESH EROSION 1 (0.57%)  0  
DEATH 0  0  
 
Table 7. Comparison of the surgical complications in patients subjected to surgery  
because of GERD or BE 
 
4.5. ENDOSCOPIC TREATMENT OF SPONTANEOUS ESOPHAGEAL RUPTURE, 
A COMPLICATION DEVELOPED ON THE BASIS OF BE 
 
In this section, we present the minimally invasive treatment strategy of spontaneous 
esophageal rupture (Boerhaave’s syndrome), a rare condition associated with BE. A 53-year-
old male patient with lower-third rectal adenocarcinoma (T2N1) was admitted. He was known 
to have gastroesophageal reflux disease complicated with Barrett’s esophagus (intestinal 
metaplasia with low-grade dysplasia). On the second postoperative day after a low anterior 
rectal resection, forceful vomiting occurred and was followed by chest pain without clinical 
signs of esophageal perforation. The immediate chest x-ray revealed only a small amount of 
pleural effusion on the right. The follow-up chest x-ray (acquired 12 hours later), however, 
demonstrated an increase in the amount of the pleural effusion, and hydropneumothorax was 
developed. A contrast swallow with a water-soluble contrast agent confirmed the presence of 
a transpleural esophageal rupture (Figure 1). The immediate upper gastrointestinal endoscopy 
showed a mucosal rupture of 5 to 7 mm in length on the posterior wall of the esophagus, 4 cm 
above the gastroesophageal junction. The mucosal tear was successfully closed with 3 
endoscopic clips (Olympus Quick Clip 2) (Figure 2). The endoscopic closure was 
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supplemented with right thoracic drainage, gastrostomy and catheter feeding jejunostomy. 
Eight days after the endoclip application, esophagography demonstrated no further leakage, 
and oral feeding could be resumed. There were no complications and the patient was 
eventually discharged 14 days after the endoscopic intervention. Control endoscopy showed 
only scar tissue at the site of the closed perforation with LGD of BE. 
 
 
 
 
 
Figure 2. Left: The contrast material leakage site is to the left, above the cardia that slipped 
through the hiatal hernia. Right: Placement of an endoscopic clip to close the perforation 
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5. DISCUSSION 
 
Reflux disease affects more than one third of the population, and it may range from an 
asymptomatic condition through a condition without inflammatory signs (non-erosive reflux 
disease) to a symptomatic condition accompanied by severe erosion and its complications that 
considerably worsen the quality of life. Parallel to this, the incidence of esophageal 
adenocarcinoma shows an increase in the developed world. In the presence of Barrett’s 
metaplasia developed on the basis of reflux, the risk of developing esophageal 
adenocarcinoma is 30 to 125 times higher than in the normal population.
[39,40]
 
 
5.1. ACID REFLUX, THE MOST LIKELY TRIGGERING FACTOR OF 
METAPLASIA 
The pathomechanism of GERD involves (among other factors) changed dietary habits, 
overweight, increased abdominal pressure, and the anatomical defects (hiatal hernia) 
developed due to these, which increase the reflux that is already physiologically present by 
overcoming the barrier function of the cardiac region. Based on our preoperative assessment, 
patients were overweight in a considerable percentage and the prevalence of hiatal hernia was 
the same in the GERD and BE groups. 
  
It has been known for a long time that in some cases, depending on the severity of the reflux, 
the acidic gastric contents regurgitating into the esophagus may cause symptoms only, 
whereas in other cases, they may damage the squamous epithelium lining the esophagus, 
resulting in erosion, inflammation and, later, ulceration and stricture.
[5]
 
In the development of reflux esophagitis, at the microscopic level, the opening and widening 
of the gap between mucosal cells play a role. It was successfully triggered under experimental 
conditions with both mild and severe acid or mixed reflux.
[41]
 At the site of the epithelial 
defect that is developed in case of persistent reflux, the regeneration starting from the 
submucosal pluripotent Schaffer glands may result in that columnar epithelium, which is more 
resistant to the acidic environment, replaces the squamous epithelium, i.e., Barrett’s 
esophagus is developed. Its predictive factors are the total time of acid reflux, its severity and 
the consequentially worsening lower esophageal sphincter (LES) function.
[13,42,43,44,45,46,47,48]
 
Our study supports the observation that the exposure to reflux is longer and more severe in the 
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group of patients with Barrett’s metaplasia than in the group of patients with reflux alone. In 
our sample, however, no difference was found between the two groups in the duration of 
complaints and the LES impairment. Nevertheless, the mean history of 5.6 years is in 
accordance with the observation of Öberg who found that approximately the same time 
(6.2 years) is required for the columnar epithelial metaplasia to appear as a result of the 
increased exposure to acid.
 [49]
 It can be established, based on the above, that one of the most 
important factors in the squamous–columnar transformation is the appearance of acid in the 
esophagus.  
This process theory is contradicted by the subgroup theory of Fass, according to which the 
different subgroups of GERD (non-erosive GERD, erosive GERD and complicated GERD) 
should be treated as separate entities, and there is only limited transition between them.
[50]
 
The difference between the uncomplicated GERD and BE subgroups appears to be confirmed 
also by molecular genetic studies, according to which the expression of a possible marker of 
dysplastic processes, the cdx-2 gene, can be detected both in the intact and in the metaplastic 
epithelium of patients in the BE group, whereas it is absent in the mucosa of patients with 
reflux alone.
[51]
 According to this theory, reflux patients cannot be sorted into the same risk 
group with regard to the course of the disease, and there may be a difference also in the 
treatment strategy based on this. 
 
5.2. DEVELOPMENT AND RISK FACTORS OF BARRETT’S ESOPHAGUS 
 
The driving force behind the transition within the columnar epithelium and the appearance of 
intestinal metaplasia and dysplasia is the bile that is mixed with acid reflux. Bile acids that are 
in non-ionized but still solute form in the pH range of 3 to 5 of the acid mixed with the 
alkaline saliva in the esophagus are able to diffuse into the cells through the mucosal 
membrane, and return there to mostly ionized form at the intracellular pH, thus getting 
trapped and accumulating in the cells. Here, they may trigger the dysplastic processes by 
damaging the mitochondria of the cells. However, they may have a role not only in triggering 
carcinogenesis but also in the differentiation to adenocarcinoma.
 [13]
 
In the acidic–biliary environment, several “evolutionary responses” may appear often parallel 
to each other (fundic, cardiac and intestinal or even respiratory ciliary columnar epithelium, 
pancreatic acinar or ductal metaplasia, or low-grade, high-grade dysplasia or even in situ 
carcinoma). It is supposed that Schaffer glands have an important role in the development of 
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this diverse picture, because their pluripotent germ cells may be responsible for the 
heterogeneous responses to the inflammatory damage. 
[8]
 Besides the simultaneous presence 
of metaplasias, transformation into each other may also be supposed. Nevertheless, many of 
the above forms of metaplasia and dysplasia may be present in the mucosa even at the same 
time. 
[8]
 
A true risk of potential malignancy is associated with the appearance of IM.
[28, 52]
 However, it 
is a known fact that the malignant transformation of non-intestinal epithelium cannot be 
excluded either, although its estimated risk is considerably lower (0.07% annually) than in the 
concomitant presence of intestinal metaplasia (0.38% annually).
[28, 52]
 In other publications, 
the rate of dysplasia and carcinoma was almost the same in case of non-intestinal metaplasia 
than in IM. It must be added, however, that during the 5-year follow-up of this group, IM 
appeared in more than 50% of the cases, and this ratio reached 90% after 10 years.
[53]
 It 
appears to support our conclusions below about the possible limitations of biopsy and the 
ability of metaplastic processes to transform into each other. 
Although multiple biopsy samples may help assess the precise status of BE, only the 
momentary status of a small area can be assessed this way, which makes it hard to evaluate 
the efficacy of the treatment and the change in the condition. During the endoscopic 
examinations, multiple sampling is performed as per the Seattle protocol: on the one hand, 
from the visible Barrett lesions themselves, and on the other hand, from each esophageal 
quadrant with 2 cm intervals
[26]
. Increasing the number of biopsy samples clearly improves 
the ability to detect IM. According to the results of Harrison et al., with only 4 samples taken 
from the same patients, IM could be detected in only half of the IM cases previously 
confirmed with samples taken from 8 biopsy sites.
[54]
  
In view of the above, we still consider it important, when Barrett’s esophagus is developed, 
not to focus only on intestinal metaplasias (that are confirmed to carry the potential for 
malignant transformation) but to follow non-intestinal (fundic and cardiac) metaplasias and 
other histological phenotypes as well. 
 
In case of metaplasia or dysplasia, compared with patients with reflux disease alone, the 
presence of a larger hiatal hernia, more frequent LES insufficiency and more severe acid and 
bile reflux are assumed. Based on the above, the presence of a more frequent and more 
aggressive reflux is likely in tumorigenesis.
[13, 28]
 
Additional risk factors may include old age, male gender, Caucasian race and overweight.
[28]
 
Smoking may also increase the risk.
 [28]
 Family history should also be assessed, since BE can 
be detected in almost one-fourth of the first-degree relatives of an individual with lower-third 
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esophageal adenocarcinoma.
 [28]
 Attention should be paid to this also when planning the 
follow-up and screening of patients. 
In the clinical practice, long-term antacid treatment (with proton-pump inhibitors) is worth 
mentioning - it may even facilitate carcinogenesis in case of Barrett metaplasia because the 
achlorhydria developed in the stomach helps the bile acids reach the esophagus without 
precipitation, and the treatment may create a more favorable environment for the intracellular 
migration of bile acids by changing the pH in the distal segment of the esophagus. 
Although the large meta-analyses have supported the trend only, it seems that the annual risk 
of developing adenocarcinoma is higher in the case of LSBE than in the case of SSBE. When 
comparing the two patient populations based on the length of BE, patients with 
adenocarcinoma had a significantly longer BE segment.
[28]
 At the same time, the risk of 
esophageal cancer was lower in case of SSBE than in the other non-dysplastic BE groups. 
[28, 
55]
 
The theory according to which bacterial colonization, and metabolites produced during 
bacterial metabolism, are potentially carcinogenic, was not supported by the Helicobacter 
pylori infection observed in the stomach. H. pylori infection was more common in patients 
with GERD (27% vs. 10%). It rather corresponds to the relatively low infection rate observed 
in BE by Nam et al., and correlates with the more common and more severe erosive reflux 
disease observed by them in the absence of H. pylori.
[56]
 
 
The appearance of dysplasia and the length of BE further increase the risk of developing 
cancer. The presence of LGD means a 5- to 6-fold increase in the risk of malignant 
transformation (HGD and adenocarcinoma) compared with the non-dysplastic BE 
population.
[28, 57]
 Based on the above, we suppose that a more severe acid-bile reflux has a 
pathogenic role in the development of dysplasia. Because of this, patients with BE in our 
study were assigned to three different groups based on the presence of conditions indicating 
carcinogenesis or its risk, depending on whether the histological sample taken during the 
endoscopy showed non-intestinal (i.e., fundic or cardiac) metaplasia (Group 1), intestinal 
metaplasia (Group 2) or low-grade dysplasia on the basis of the latter (Group 3). Taking into 
account that parallel metastatic and dysplastic conditions were likely in the biopsy samples, 
patients were always sorted based on the most severe condition found. 
Patients with BE reported a mean duration of complaints of 5.6 years before the surgery. It 
was not different from the length of history reported by patients who underwent surgery 
because of GERD. There was no correlation between the severity of Barrett metaplasia 
(intestinal metaplasia and low-grade dysplasia) and the duration of complaints either and, 
35 
 
paradoxically, reflux complaints of longer duration were observed in the non-intestinal group, 
compared to the intestinal one. There were no differences in patient demographics (age, BMI, 
etc.) in the case of BE or, within this group, LGD. 
When comparing patients who suffer from GERD with those who have BE, the more severe 
acid reflux confirmed in the BE group may cause metaplasia but a further role of acid reflux 
in the metaplasia–dysplasia transition in the BE subgroups could not be confirmed in the 
second half of our study. Nevertheless, our study showed that bile reflux was significantly 
more common and more severe in the low-grade dysplasia (LGD) group of BE patients than 
in the groups of patients with non-dysplastic metaplasia.
[58]
 
Our hypothesis that changes in the anatomy of the gastroesophageal junction, a larger hiatal 
hernia or decreased LES pressure, decreased LES relaxation time, or a shorter LES, are more 
common in case of LGD, was not confirmed. 
 
5.3. THE PLACE OF SURGERY IN THE TREATMENT OF REFLUX AND 
BARRETT’S ESOPHAGUS 
 
In view of the above pathophysiology, it seems logical that restoring the impaired function of 
the GEJ may be the most effective treatment of the condition. But can we treat a disease that 
is mostly considered functional with a surgical procedure?  
 
Conservative and surgical therapies are both accepted in the treatment of reflux, which has a 
central role in the development of the above mucosal transformation. With minimally invasive 
surgery becoming part of everyday practice, we can say that the morbidity risk of the 
laparoscopic antireflux surgery is low compared to its possible benefits to the patients.
[59]
 The 
advantage of laparoscopic antireflux surgery over conservative therapy is that it attempts to 
restore the previous anatomical situation, i.e., it eliminates hiatal hernia by reconstructing the 
posterior diaphragmatic crus, restores the angle of His by retracting the lower portion of the 
esophagus into the abdomen, and restores the LES function with fundoplication. Unlike 
proton-pump inhibitors, it may eliminate not only acid reflux but also bile reflux. Compared 
with the permanent, lifelong medical treatment, it may be considered cost effective. However, 
opinions are divided on its long-term efficacy.
[60, 61]
 A long-term complaint-free status can be 
expected in case of a correctly performed antireflux surgery. It can be established based in the 
36 
 
LOTUS trial that, regarding long-term efficacy, laparoscopic antireflux procedure is as 
effective as medical treatment.
 [62]
 
At the same time, the indications for laparoscopic antireflux surgery show considerable 
differences around the world. The practice of our department follows the SAGES 
guidelines.
[63]
 Primarily, those reflux patients undergo surgery who do not respond to 
conservative therapy due to mixed or alkaline reflux, volume reflux, or a proximal reflux 
presenting with extraintestinal manifestation. The surgical solution may be preferred in young 
patients because of the need for permanent medical treatment, and in patients with poor 
compliance because of the frequency of relapses. Surgery is recommended also in the case of 
a large hiatal hernia accompanied by reflux. A further indication for surgery is if 
complications of GERD are developed. In the treatment of BE (one of the complications), 
surgery may be a treatment alternative that, besides eliminating the symptoms, may prevent 
the metaplasia - dysplasia - adenocarcinoma transition. 
Our patients, therefore, had heterogeneous indications for surgery but the procedure was 
mostly performed after an unsuccessful conservative therapy. In our study, the patients in both 
groups underwent surgery after a mean 19 to 20 months of unsuccessful medical treatment. 
Our early postoperative functional examinations confirmed that laparoscopic antireflux 
surgery could achieve improvement, i.e., good reflux control, even in this presumably selected 
patient population with poorer prognosis and poorer response to conservative therapy 
(unsuccessful after a mean duration of one year and a half). LES pressure returned to the 
physiological range and the DeMeester score, which best describes acid reflux, decreased to 
normal values in both groups. Surgical treatment, therefore, may have additional advantages 
over medical treatment. Our results, however, must be considered to be of limited value 
because of the short follow-up of the functional examinations. Its mean duration did not 
exceed eighteen months in either group. 
A further advantage of laparoscopic antireflux surgery is that it can be standardized, and 
therefore the steps of the procedure can be reconstructed later at any time, and the results from 
different institutions are comparable.
[62]
 The arguments in favor of performing the surgeries in 
larger centers include - besides the high number of surgeries, which means adequate 
experience - the close cooperation between the surgeon and the gastroenterologist: at the time 
of making the correct indication for surgery and, naturally, during the implementation of the 
appropriate follow-up.
[64, 65, 66]
 
 
Numerous studies have confirmed the advantages of the laparoscopic technique over the 
antireflux surgery performed with the conventional method. The question today is which of 
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the numerous laparoscopic antireflux procedures is more beneficial, what antireflux barrier 
we should create. Nissen’s fundoplication creates a relatively stronger reflux barrier than 
partial fundoplication.
[67]
 Dysphagia and also later dilation are more common in case of a 360-
degree fundoplication but only among patients with decreased esophageal motility. In case of 
normal esophageal function, there is no difference between the two types of surgery. In case 
of total fundoplication, the “gas bloat” phenomenon is also more common.[68, 69] When 
comparing the partial anterior surgery and Nissen’s fundoplication, dysphagia- and “gas 
formation”-related complaints are less common in case of anterior fundoplication, the 
reoperation rate is therefore also lower and, as a direct consequence, patients are more 
satisfied than after Nissen’s procedure.[70] However, the recurrence of reflux symptoms 
(heartburn) and the need for restarting antacids is more common in this group, which suggests 
that Nissen’s fundoplication may provide the best reflux control in the long term.[67, 68, 69, 70] 
 
The closure strategy of larger hiatal hernias is also an important issue. Although hiatal hernia 
was common in both patient groups (69.32% and 64.1%), its mean size was only 3.5 and 
3.73 cm, respectively and, therefore, a mesh was placed in a mere 5.5% of all cases. In these 
cases, the placement of the mesh was warranted by, besides the size of the hiatus, the 
unsuccessful tension-free closure of the diaphragmatic crura. To prevent the recurrence of 
hiatal hernia, we find it necessary to reinforce the diaphragmatic crura with a mesh in case of 
more than 3 diaphragmatic stitches. Primarily, the use of a PTFE or composite mesh secured 
with a spiral clamp and covering the diaphragmatic crura is recommended. In our practice, we 
preferably avoid wrapping the esophagus around completely. To prevent erosion caused by 
the mesh, besides the choice of material (Teflon or composite mesh), it was covered with the 
omentum in a few of our cases. Based on other publications, the ligamentum teres hepatis or 
the tensor fasciae latae muscle may also be used to reinforce or replace the mesh.
[71, 72]
 
Various allo- and xenografts may also be used in these cases.
[72]
 
 
5.4. THE ROLE OF ANTIREFLUX SURGERY IN THE TREATMENT OF 
BARRETT’S ESOPHAGUS 
 
BE may be treated with medical therapy, endoscopic ablation, antireflux surgery or a 
combination of these. The advantage of surgery over medical therapy is that by restoring the 
LES function, it eliminates not only acid reflux but bile regurgitation as well. Since the first 
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observation made by Brand et al.
[73]
 (1980), it has become a generally known fact that 
antireflux surgery also creates an opportunity for the regression of BE. Based on the results of 
randomized and retrospective studies conducted to date, it can be established that antireflux 
surgery is more effective in preventing the progression of BE than medical treatment.
[74, 75, 76, 
77, 78, 79, 80, 81]
  
According to the most recent meta-analysis, antireflux surgery clearly has a beneficial effect 
on the regression of BE and dysplasia.
[82]
 It has been found in some studies that surgery does 
not lead to an obvious decrease in the occurrence of adenocarcinoma, despite the excellent 
results published by numerous institutions about the beneficial effect of laparoscopic 
fundoplication in the treatment of reflux disease.
[83, 84]
 According to a recent Swedish study, 
antireflux surgery does not prevent the development of esophageal or cardiac adenocarcinoma 
in some of the patients with GERD.
 [85]
 
The views on the role of antireflux surgery in prevention are quite contradictory in the 
literature. To date, no meta-analysis confirming or refuting a preventive effect with clear 
evidence has been published, and no large, prospective studies are expected in the near future 
either because of the special and small patient population. 
Approaching the question from the perspective of the pathophysiology of the disease, a clear 
advantage of the surgical treatment is that, unlike the medical treatment, it may eliminate not 
only acid reflux, an important factor of the development of metaplasia, but also bile reflux, 
which is essential for provoking dysplasia.  
This assumption seems to be confirmed by the fact that during the 42-month endoscopic 
follow-up of our patients subjected to surgery because of Barrett’s esophagus, an unchanged 
status was observed in 53% of the cases, and regression was detected in a further 30%. 
Progression occurred in only 17%, and all of these cases were observed in the non-intestinal 
metaplasia group. Dysplasia was not developed in the group of patients with intestinal 
metaplasia, and no further progression (to high-grade dysplasia or carcinoma) occurred in the 
low-grade dysplasia group during the study period. 
In the patient group showing regression, the postoperative functional results were 
significantly better than in the groups that did not show regression. However, we consider it 
important that the majority of our cases were short-segment BE. Based on the above, it can be 
established that in certain (presumably early) cases of BE, a laparoscopic antireflux surgery 
that provides effective reflux control may achieve regression even in patients not responding 
to medical treatment. 
Csendes et al.
 [81]
 have reached a similar conclusion. According to our observations, 
laparoscopic antireflux surgery is associated with a low morbidity rate, and may decrease the 
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subjective complaints of short-segment BE patients in the long term (Visick Grade I and 
Grade II in 86.3 to 100% of the patients), it leads to the regression of intestinal metaplasia 
(IM) in one-thirds of the patients, and the IM does not progress to LGD, HGD or 
adenocarcinoma. In case of BE, surgical treatment should be considered also according to 
DeMeester et al., because they often observed the regression of LGD after antireflux 
surgery.
[13]
 The regression of IM is more common in the group of patients treated surgically 
than in those who receive medical treatment.
[82]
 A randomized study comparing the medical 
and surgical treatment has confirmed that a correctly performed antireflux surgery 
significantly decreases the rate of reflux esophagitis and stricture, and the segmental length of 
BE also significantly decreases after the surgery.
 [80]
 The rate of new-onset dysplasia was 
statistically different between the surgery group and the medically treated group (2% vs. 20%, 
respectively).
[75, 86, 87, 88, 89]
 At the same time, the risk of malignant transformation was not 
lower than in the medically treated group. However, the same incidence of developing cancer 
in the two groups may be influenced by the fact that surgical treatment is performed in 
patients with more severe reflux - after medical treatment has failed.
[86, 87, 89, 90]
 A preventive 
effect of laparoscopic antireflux surgery on the development of adenocarcinoma was not 
confirmed by the Swedish cohort study published by Lagergren et al. either.
[91, 92]
 It must be 
noted, however, that this study compared the rate of adenocarcinoma with that in the healthy 
population and not in patients with reflux.
 [93] A “new-onset” BE developed after the antireflux 
surgery and the progression of an already present BE raise many concerns against the surgical 
treatment. 
In the GERD patient group, the occurrence of metaplasia during our postoperative observation 
may have two explanations. The first is unsuccessful surgery. De novo BE may be expected in 
case of inadequate reflux control. It is contradicted by the fact that the results of our 
functional examinations did not differ from those observed in patients without progression. 
The second, more likely explanation lies in the limitation of biopsy already mentioned, that is, 
that the quadrant biopsy samples “taken blindly” in case of GERD provide a histological 
picture of a small area only, which does not exclude the prior presence of Barrett metaplasia 
in other areas, recognized only at the time of the second biopsy. Nevertheless, our opinion is 
that the clinical manifestation of BE should not be considered a uniform condition.  
Although surgery that provides adequate reflux control can lead to regression (primary 
prevention) in a certain group of patients with BE, Barrett metaplasia was nonetheless 
observed after surgery in another patient group and, in a smaller portion of the patients, 
progression is not excluded either. Recognizing this patient group and following it more 
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closely are indispensable for secondary prevention, i.e., the early recognition and successful 
treatment of cancer.  
The conclusion of DeMeester et al. may possibly explain progression - if carcinogenesis 
already started before the surgery because of the mixed reflux, and the meta- and dysplastic 
cells already got out of autoregulation control due to the genetic damages, the antireflux 
surgery, obviously, does not provide protection against advanced dysplastic processes, and in 
this case, adenocarcinoma may appear within 5 years after the surgery. In case of cancers 
developed later than this, they confirmed the recurrence of reflux.
[13]
 Other studies
[94, 95, 96]
 
also point out that late adenocarcinoma following antireflux surgery can be explained by 
postoperative reflux due to an unsuccessful surgery or by recurrent reflux, and they emphasize 
the importance of pH-metry during follow-up. 
It is also possible, however, that BE does not expose to a higher risk of developing 
adenocarcinoma but appears only as a coincidence. The fact that the histological examination 
confirmed BE next to adenocarcinoma in only half of the resections performed because of 
tumor may support this theory.
[97, 98]
 Jamieson hypothesized that adenocarcinoma may be 
developed not or not only from the Barrett epithelium during tumorigenesis but the 
transformation of a pluripotent germ cell starts in response to inflammation and epithelial 
damage due to the reflux.
 [92]
 In this case, although the reflux-induced inflammation is also 
responsible for the development of BE, BE should be considered an indicator of the severity 
of reflux rather than a premalignant condition. The most likely case is that carcinogenesis 
does not occur in one way only, and dysplasia and cancer developed on the basis of BE is just 
one possible way in this process. Going ahead with this hypothesis, from the perspective of 
carcinogenesis, therefore, a successful antireflux surgery performed in time may be of 
preventive effect in certain patients with BE. Nevertheless, taking the slow progression of the 
condition and the great heterogeneity of BE into account, regular long-term endoscopic 
follow-up and biopsies are indispensable for the successful treatment of reflux disease and 
Barrett’s esophagus. To confirm whether laparoscopic antireflux surgery can prevent the 
progression of Barrett’s esophagus in the long term, repeat functional examinations to verify 
the effective functioning of the antireflux barrier are required besides endoscopic follow-up. 
 
A further open question is the alternative long-term treatment of dysplastic (LGD) BE. 
Current recommendations consider only the need for endoscopic follow-up every six months 
confirmed. Although the efficacy of the treatment may be further improved by the ablation of 
the dysplastic epithelium, this is currently not recommended due to the lack of large 
randomized studies.
[28]
 Numerous procedures are known for this, from the endoscopic 
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resection of the mucosa through radiofrequency ablation to laser, argon plasma coagulation, 
cryotherapy and photodynamic therapy. We should not forget, though, that a histological 
examination of the resected mucosa is performed and the exact depth of the dissection can be 
reconstructed only in case of endoscopic resections. In the rest of the procedures, there is less 
control of the ablation depth. The rate of potential complications (stricture and, more rarely, 
perforation) is also higher.
[28]
 Special issues are invisible lesions and recurrence in the 
submucosal glandular structures, which, in case of LGD, may reach a rate close to 10% in the 
year following the procedure. We emphasize, nevertheless, that the procedures can be 
repeated. However, in knowledge of the pathomechanism of the disease, it is worth 
combining these procedures either with minimally invasive antireflux surgery or with 
permanent acid-reducing medical treatment, which may be completed with an NSAID in 
increased dose (300 mg Aspirin) for chemoprevention.
[99]
 
 
5.5. MORBIDITY OF ANTIREFLUX SURGERY AND TREATMENT OF THE 
COMPLICATIONS OF BARRETT’S ESOPHAGUS 
 
The minimally invasive surgical treatment performed at our center was an effective treatment 
alternative to unsuccessful medical treatment, without mortality and with a low morbidity 
rate. The conversion rate of 0.6 to 1.3% is considered low. The most common reasons for 
conversion include adhesions and injuries to adjacent organs. The most common perioperative 
complications, besides minor bleeding, are pneumothorax requiring pleural drainage and 
subcutaneous emphysema that can be controlled with conservative treatment. As to late 
complications, the most common is dysphagia that requires hospitalization (1.7 to 2.6%), 
which can be considered an “efficacy indicator” of Nissen’s fundoplication. These cases often 
spontaneously resolve if adequate dietary instructions are given, and rarely need instrumental 
dilation. The most severe late complication is erosion of the esophageal wall after mesh 
placement (1.3%). Although it appears to be rare, its rate of 7.1% in patients with mesh 
placement only is high. Therefore, in our practice, besides the choice of material (Teflon or 
composite mesh), we avoid wrapping the esophagus around completely. To prevent erosion 
caused by the mesh, it was covered with an omental flap in a few cases. Other publications 
recommend the use of the ligamentum teres hepatis or the tensor fasciae latae muscle to 
reinforce or replace the mesh.
[71, 72]
 Various allo- and xenografts may also be used in these 
cases.
[72]
 
42 
 
5.6. A RARE COMPLICATION OF BE - SPONTANEOUS ESOPHAGEAL 
PERFORATION 
 
With the advance of surgical endoscopy, minimally invasive procedures have gained ground 
also in the treatment of the severe complications of BE. Their role in the diagnostics and 
therapy of both bleeding and obstruction is indisputable. Surgical treatment is required only in 
the rarest cases. A similarly rare severe complication is spontaneous perforation or 
Boerhaave’s syndrome developed on the basis of BE ulcer. According to our knowledge, the 
closure of the perforation opening with endoscopic clips that we performed in our patient is 
the first documented successful case in Hungary.  
The condition is the result of a pressure increase in the lumen of the esophagus, which is 
primarily caused by voluminous vomiting. Since our patient had known reflux disease 
complicated by BE with LGD, and esophagitis, a weakening of the distal esophageal wall 
could be assumed as well.  
The condition was considered fatal until the first successful surgical treatment performed by 
Barrett in 1947.
 [100]
 Today, despite the more effective treatment options, mediastinitis and the 
rapidly developed septic condition are often irreversible. In cases where surgery is performed 
after more than 24 hours, the mortality rate exceeds 20 to 30%.
[101]
 
The fundamental components of the treatment of esophageal rupture are the elimination of the 
septic source, the surgical or non-surgical closure of the defect, and thoracic and mediastinal 
debridement. Important parts of the therapy are the treatment of sepsis, intensive monitoring, 
targeted antibiotic/antifungal treatment, fluid therapy and increasing the ability of the body to 
resist by early enteral feeding. The treatment strategy is determined by multiple factors: the 
type of perforation (complete, intramural), its size, esophageal comorbidities, the time of 
making the diagnosis (delay), the presence of septic complications and the general condition 
of the patient. Choosing an individually tailored therapy requires considerable experience and 
availability of different therapeutic modalities.
[102]
 According to literature data, the healing 
rate of primary esophageal suture completed with mediastinal and thoracic drainage exceeds 
90% in cases where the esophageal injury is treated within 24 hours and is not complicated by 
other esophageal conditions (tumor, stricture, etc.).
[103, 104]
 
In the past years, several cases of successful use of endoscopic clips and self-expanding stents 
in the treatment of esophageal rupture have been reported.
[105, 106]
 Closure of an esophageal 
injury with endoscopically placed clips was first performed in 1995 (the injury occurred 
during pneumatic dilation in a patient with achalasia).
[107]
 Since then, the method has been 
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used in esophageal perforations of several different etiologies, including Boerhaave’s 
syndrome.
[108, 109, 110, 111, 112]
 Currently, the procedure can be used in case of small injuries 
(< 1.5 cm) only. The method is suitable for the endoscopic closure of chronic spontaneous 
esophageal rupture and the consequential fistula.
[113, 114]
 In our case, the complete esophageal 
perforation (with a rupture on the esophageal wall and also the mediastinal pleura) was 
detected within 24 hours. Since the visible rupture on the esophagus was only 5 to 7 mm, it 
could be successfully closed with endoscopic clips. Placing tubes surgically or with less 
invasive methods into the infected mediastinum and the chest, and debridement are 
indispensable for healing.  
Endoscopic stents have been successfully used in the treatment of different types of 
esophageal perforation, including Boerhaave’s syndrome.[115, 116, 117, 118, 119, 120]  
It is well known that suture failure may occur also after the early primary surgical closure of 
esophageal rupture. Endoscopic clipping or stent placement may be useful therapeutic 
methods also in this case. Smaller defects can be treated and, therefore, more extensive 
surgical exploration can be avoided with their use.
[121]
 
Based on the reports, the endoscopic placement of self-expanding stents is also a safe 
procedure associated with minimal mortality and morbidity rates.
[122]
 The success of this 
procedure also depends on the early use of the method. Similarly to other therapeutic options, 
the chance of healing in case of esophageal perforation is considerably decreased by any 
delay in the endoscopic treatment.  
The use of a minimally invasive technique has also appeared in the treatment of Boerhaave’s 
syndrome.
[123, 124]
 Avoiding thoracotomy, which is associated with a high rate of morbidity, 
may have considerable benefits for patients in severe condition. We know of several reported 
cases where a laparoscopic or thoracoscopic method was used in the treatment of spontaneous 
esophageal rupture.
[123, 124, 125, 126, 127, 128, 129]
 
To summarize, we can establish based on the available experience that endoscopic and 
minimally invasive surgical methods, if proper conditions are met, may be therapeutic 
alternatives in the treatment of Boerhaave’s syndrome developed on the basis of BE. 
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SUMMARY, OUR MOST IMPORTANT RESULTS 
 
1. The severity of the pathological acid reflux developed parallel to the incompetent 
functioning of the impaired lower esophageal sphincter potentiates, besides the 
inflammation in the lower third of the esophagus, the start of metaplastic processes 
and, ultimately, the development of Barrett’s esophagus. 
 
2. In response to the bile reflux accompanying the acid reflux, dysplastic changes may 
start in the metaplastic columnar epithelium (that appeared due to acid reflux). 
 
3. In selected GERD and BE patients resistant to medical treatment, Nissen’s correctly 
performed laparoscopic surgery can successfully control (eliminate or decrease) 
gastroesophageal reflux and is associated with a low morbidity rate. 
 
4. The antireflux surgery may stop the progression of Barrett’s esophagus and result in 
regression in some patients. Nevertheless, further long-term follow-up is required to 
confirm the assumed preventive effect of antireflux surgery in the process of 
carcinogenesis. 
 
5. Endoscopic methods, if proper conditions are met, may be therapeutic alternatives in 
the treatment of esophageal perforation. 
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